{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:00:58Z","timestamp":1784966458263,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cllc.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:39Z","timestamp":1778760459000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression &lt; 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7154-8692","authenticated-orcid":false,"given":"Isadora","family":"Mamede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Lara","family":"Nohmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israt Jahan","family":"Riya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifrat Jahan","family":"Piya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonious","family":"Hazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1865-5801","authenticated-orcid":false,"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16_suppl","key":"10.1016\/j.cllc.2026.05.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e23276","article-title":"Cancer statistics: the United States vs. worldwide","volume":"42","author":"Desai","year":"2024","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.cllc.2026.05.003_bib0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","article-title":"Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study","volume":"13","author":"Luo","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.cllc.2026.05.003_bib0003","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.05.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cllc.2026.05.003_bib0005","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cllc.2026.05.003_bib0006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.05.003_bib0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10459","key":"10.1016\/j.cllc.2026.05.003_bib0008","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cllc.2026.05.003_bib0009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/M15-0930","article-title":"The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses","volume":"162","author":"Cornell","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.05.003_bib0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.05.003_bib0011","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cllc.2026.05.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.cllc.2026.05.003_bib0013","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cllc.2026.05.003_bib0014","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"OA13.03 perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial","volume":"19","author":"Heymach","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.05.003_bib0015","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non\u2013small cell lung cancer: the TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.05.003_bib0016","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2026.05.003_bib0017","doi-asserted-by":"crossref","unstructured":"Yue D, Wang W, Liu H, et al. MA04.08-perioperative tislelizumab for resectable non-small cell lung cancer: final analysis of RATIONALE-315. WCLC 2025. Available at https:\/\/www.beonemedinfo.com\/CongressDocuments\/Yue_BGB-A317-315_WCLC_Abstract_2025.pdf. Accessed on September 8, 2025.","DOI":"10.1016\/j.jtho.2025.09.128"},{"issue":"12","key":"10.1016\/j.cllc.2026.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.05.003_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.05.003_bib0020","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/jnci\/djaf090","article-title":"Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis","volume":"117","author":"Nuccio","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2026.05.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113404","article-title":"Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies","volume":"195","author":"Nuccio","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.05.003_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12890-025-03479-2","article-title":"Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.cllc.2026.05.003_bib0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmjebm-2022-111928","article-title":"Theory and practice of Bayesian and frequentist frameworks for network meta-analysis","volume":"28","author":"Sadeghirad","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.cllc.2026.05.003_bib0024","doi-asserted-by":"crossref","first-page":"S647","DOI":"10.1016\/j.jval.2020.08.1466","article-title":"PNS22 network meta-analysis: a comparison of Bayesian and frequentist approaches to synthesis, and evaluation of their suitability for decision-making","volume":"23","author":"Harvey","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.cllc.2026.05.003_bib0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.05.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107799","article-title":"Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis","volume":"191","author":"Zhang","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.05.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78159-y","article-title":"The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis","volume":"14","author":"Mo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2026.05.003_bib0028","article-title":"Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.cllc.2026.05.003_bib0029","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.05.003_bib0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.05.003_bib0031","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non\u2013small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.05.003_bib0032","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.05.003_bib0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.05.003_bib0034","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","article-title":"Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer","volume":"16","author":"Hwang","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.05.003_bib0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5858\/arpa.2023-0536-CP","volume":"148","author":"Sholl","year":"2024","journal-title":"Arch Pathol Lab Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:20:49Z","timestamp":1784964049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525730426000719"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}